Importantly, when combined with the R-CHOP regimen, the PI3K/AKT inhibitor converted CSCs to differentiated cancer cells by destabilizing SOX2 level, thus inhibiting the growth of resistant cells that were highly sensitive to the R-CHOP regimen (Chen et al., 2020). The gene discussed is AKT1; the disease is cancer.